CureVac N.V. (5CV.F)
EUR 3.15
(-2.48%)
EUR 3.15
(-2.48%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 271.53 Million EUR | -17.02% |
| 2022 | 327.21 Million EUR | -30.34% |
| 2021 | 469.76 Million EUR | -41.28% |
| 2020 | 800 Million EUR | 361.31% |
| 2019 | 173.42 Million EUR | 85.33% |
| 2018 | 93.57 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 180.4 Million EUR | -25.96% |
| 2024 Q1 | 243.51 Million EUR | -10.32% |
| 2023 Q2 | 250.43 Million EUR | -3.78% |
| 2023 FY | 271.53 Million EUR | -17.02% |
| 2023 Q1 | 260.27 Million USD | -20.46% |
| 2023 Q3 | 240.3 Million EUR | -4.05% |
| 2023 Q4 | 271.53 Million EUR | 13.0% |
| 2022 Q3 | 285.52 Million EUR | -5.65% |
| 2022 Q2 | 302.61 Million EUR | -13.98% |
| 2022 Q1 | 351.79 Million EUR | -25.11% |
| 2022 FY | 327.21 Million EUR | -30.34% |
| 2022 Q4 | 327.21 Million EUR | 14.6% |
| 2021 Q4 | 469.76 Million EUR | -51.46% |
| 2021 Q3 | 967.83 Million EUR | 0.22% |
| 2021 Q1 | - EUR | -100.0% |
| 2021 FY | 469.76 Million EUR | -41.28% |
| 2021 Q2 | 965.72 Million EUR | 0.0% |
| 2020 Q1 | 199.31 Million EUR | 14.93% |
| 2020 Q4 | 800 Million EUR | 207.04% |
| 2020 Q3 | 260.55 Million EUR | 0.0% |
| 2020 Q2 | - EUR | -100.0% |
| 2020 FY | 800 Million EUR | 361.31% |
| 2019 Q1 | - EUR | 0.0% |
| 2019 FY | 173.42 Million EUR | 85.33% |
| 2019 Q4 | 173.42 Million EUR | 0.0% |
| 2018 FY | 93.57 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| BioNTech SE | 2.76 Billion EUR | 90.163% |
| Biotest Aktiengesellschaft | 945.4 Million EUR | 71.279% |
| Biotest Aktiengesellschaft | 945.4 Million EUR | 71.279% |
| BRAIN Biotech AG | 47.92 Million EUR | -466.6% |
| Formycon AG | 387.61 Million EUR | 29.947% |
| Heidelberg Pharma AG | 21.01 Million EUR | -1192.194% |
| Medigene AG | 10.65 Million EUR | -2449.593% |